Skip to main navigation
Skip to search
Skip to main content
Pure University (For Demo Only) Home
Help & FAQ
English
中文
Home
Profiles
Research units
Research output
Equipment
Datasets
Activities
Prizes
Impacts
Projects
Press/Media
Search by expertise, name or affiliation
Bimekizumab versus Adalimumab in Plaque Psoriasis
R. G. Langley
Inernational Relations Division
Research output
:
Contribution to journal
›
Article
›
peer-review
155
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Bimekizumab versus Adalimumab in Plaque Psoriasis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Pharmacology, Toxicology and Pharmaceutical Science
Adalimumab
100%
Adverse Event
7%
Bimekizumab
100%
Diarrhea
15%
Disease
15%
Immunoglobulin G1 Antibody
7%
Interleukin 17
7%
Interleukin 17F
7%
Physical Disease by Body Function
7%
Psoriasis
38%
Psoriasis Vulgaris
100%
Thrush
15%
Tumor Necrosis Factor Inhibitor
7%
Upper Respiratory Tract Infection
7%
Keyphrases
Skin Score
7%